Affiliation:
1. State Scientific Research Test Institute of Military Medicine, Ministry of Defense of the Russian Federation
Abstract
The purpose of the study was to study the specific activity of the drug molgramostim (Neostim®) under conditions of a single general γ-irradiation. Evaluation of the anti-radiation efficacy of the conducted studies, studying the 30-day survival rate and life expectancy of irradiated (at doses of 4, 5, 6, 7, 8 Gy) mice, as well as the dynamics of peripheral blood, extramedlar and bone marrow hematopoiesis. It has been established that 14-fold (with an interval of 12 hours) subcutaneous administration of the drug molgramostim at a dose of 5 μg/kg to mice after irradiation at an average lethal dose (6 Gy) has a pronounced anti-radiation effect. The value of the dose change factor when the drug is administered at the optimal dose is 1.16. The use of molgramostim increases the survival rate of mice by 30%, contributes to an earlier, compared with irradiated ani-mals of the control group, restoration of the content of peripheral blood cells (by day 10, the number of leukocytes was 50% more, and the number of lymphocytes, erythrocytes and platelets – by 10% than in animals that did not receive the drug), as well as an increase in the number of endogenous CFU by 30% compared with the control and the number of bone marrow myelokaryocytes by an average of 1.2 times.
Publisher
The Russian Academy of Sciences
Reference30 articles.
1. Васин М.В. Противолучевые лекарственные средства. М., 2010. 180 с. [Vasin M.V. Protivoluchevye lekarstvennye sredstva. M., 2010. 180 p. In Russ.)]
2. Гладких В.Д., Баландин Н.В., Башарин В.А. и др. Состояние и перспективы развития средств профилактики и лечения радиационных поражений. М.: Комментарий, 2017. 304 с. [Gladkix V.D., Balandin N.V., Basharin V.A. et al. Sostoyanie i perspektivy` razvitiya sredstv profilaktiki i lecheniya radiacionny`h porazhenij. M.: Kommentarij, 2017. 304 p. (In Russ.)]
3. Гребенюк А.Н., Гладких В.Д. Современное состояние и перспективы разработки лекарственных средств для профилактики и ранней терапии радиационных поражений // Радиац. биология. Радиоэкология. 2019. Т. 59. № 2. С. 132–149. [Grebenyuk A.N., Gladkix V.D. Modern condition and prospects for development of medicines for prevention and early treatment of radiation injures // Radiation Biology. Radioekology. 2019. V. 59. № 2. Р. 132–149. (In Russ.)]. https://doi.org/10.1134/S0869803119020085
4. Симбирцев А.С., Кетлинский С.А. Перспективы использования цитокинов и индукторов синтеза цитокинов в качестве радиозащитных препаратов // Радиац. биология. Радиоэкология. 2019. Т. 59. № 2. С. 170–176. [Simbirtsev A.S., Ketlinsky S.A. Perspectives for cytokines and cytokine synthesis inducers as radioprotectors // Radiation Biology. Radioekology. 2019. V. 59. № 2. P. 170–176. (In Russ.)]. https://doi.org/10.1134/S0869803119020164
5. Рождественский Л.М. Проблема разработки отечественных противолучевых средств в кризисный период: поиск актуальных направлений развития // Радиац. биология. Радиоэкология. 2020. Т. 60. № 3. С. 279–290. [Rozhdestvensky L.M. Difficulties in radiation counter measure preparations development in russia in crysis period: actual approaches searching // Radiation Biology. Radioekology. 2020. V. 60. № 3. P. 279–290. (In Russ.)]. https://doi.org/10.31857/S086980312003011X